226 LONG-TERM ANTIBIOTIC AND PROTON-PUMP INHIBITOR USE ARE STRONG PREDICTORS OF RECURRENT INFECTIONS IN CIRRHOSIS: A PROSPECTIVE MULTI-CENTER STUDY FROM NACSELD

Background: The prevalence of gastric polyps is unknown in Hungary. Aim: The aim of the authors was to assess the prevalence of polypoid lesions of the stomach in the endoscopic centre of the 2nd Department of Medicine, Semmelweis University. Methods: Results of upper gastrointestinal endoscopies carried out between March 2010 and June 2011 were analysed. Results: 193 cases with polyps were diagnosed in 4174 endoscopies (4.62%). Hyperplastic polyps, fundic gland polyps and malignant lesion were detected in 33.67%, 31.09% and 2.07% of the cases, respectively. Proton pump inhibitor use was more frequent among patients diagnosed with fundus gland polyps (p = 0.007), while hyperplastic polyps were diagnosed more frequently in patients with chronic gastritis (p = 0.032). Conclusions: The frequency of gastric polyps was higher than expected from data published in the literature. Long-term proton pump-inhibitor use and chronic gastritis were associated with fundus gland and hyperplastic polyps, respectively. Orv. Hetil., 2013, 154, 770–774.

Download Full-text

When does proton pump inhibitor treatment become long term? A scoping review

BMJ Open Gastroenterology ◽

10.1136/bmjgast-2020-000563 ◽

2021 ◽

Vol 8 (1) ◽

pp. e000563

Author(s):

Peter Fentz Haastrup ◽

Dorte Ejg Jarbøl ◽

Wade Thompson ◽

Jane Møller Hansen ◽

Jens Søndergaard ◽

...

Keyword(s):

Proton Pump Inhibitor ◽

Proton Pump ◽

Cochrane Library ◽

Clinical Context ◽

Eligibility Criteria ◽

Proton Pump Inhibitor Treatment ◽

Common Definition ◽

Definition Of ◽

Inhibitor Treatment

ObjectiveProton pump inhibitor (PPI) use has risen substantially, primarily driven by ongoing use over months to years. However, there is no consensus on how to define long-term PPI use. Our objectives were to review and compare definitions of long-term PPI use in existing literature and describe the rationale for each definition. Moreover, we aimed to suggest generally applicable definitions for research and clinical use.DesignThe databases PubMed and Cochrane Library were searched for publications concerning long-term use of PPIs and ClinicalTrials.gov was searched for registered studies. Two reviewers independently screened the titles, abstracts, and full texts in two series and subsequently extracted data.ResultsA total of 742 studies were identified, and 59 met the eligibility criteria. In addition, two ongoing studies were identified. The definition of long-term PPI use varied from >2 weeks to >7 years. The most common definition was ≥1 year or ≥6 months. A total of 12/61 (20%) of the studies rationalised their definition.ConclusionThe definitions of long-term PPI treatment varied substantially between studies and were seldom rationalised.In a clinical context, use of PPI for more than 8 weeks could be a reasonable definition of long-term use in patients with reflux symptoms and more than 4 weeks in patients with dyspepsia or peptic ulcer. For research purposes, 6 months could be a possible definition in pharmacoepidemiological studies, whereas studies of adverse effects may require a tailored definition depending on the necessary exposure time. We recommend to always rationalise the choice of definition.

Download Full-text

Long term management of modera te/severe peptic esophagitis in children/adolescents. H2 blocker vs proton pump inhibitor (PPI)

Gastroenterology ◽

10.1016/s0016-5085(98)80208-4 ◽

1998 ◽

Vol 114 ◽

pp. A51 ◽

Cited By ~ 3

Author(s):

B Abdullah ◽

SK Gupta ◽

JF Fitzgerald ◽

SKF Chong ◽

JM Croffie

Keyword(s):

Proton Pump Inhibitor ◽

Proton Pump ◽

Peptic Esophagitis ◽

H2 Blocker ◽

Term Management

Download Full-text

Long-term proton pump inhibitor use and the incidence of gastric cancer: A systematic review and meta-analysis

Journal of Gastric Surgery ◽

10.36159/jgs.v2i1.17 ◽

2020 ◽

Vol 2 (1) ◽

pp. 1-11

Author(s):

Ju-Li Lin ◽

Jian-Xian Lin ◽

Chao-Hui Zheng ◽

Jian-Wei Xie ◽

Jia-bin Wang ◽

...

Keyword(s):

Gastric Cancer ◽

Systematic Review ◽

Proton Pump Inhibitor ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Meta Analysis ◽

Inclusion Criteria ◽

Risk Ratios

Background: There are controverted whether the long-term use of proton pump inhibitors (PPI) will increase the risk of gastric cancer. We performed a meta-analysis to assess the risk of gastric cancer in PPI users compared with non-PPI users. Methods: The main inclusion criteria were original studies reporting the incidence of gastric cancer in PPI users compared with non-PPI users. Key outcomes were the risk ratios (RR) for gastric cancer in association with PPI users or non-PPI users. Results: We analyzed data from 8 studies, comprising more than 927,684 patients. The risk of gastric cancer in PPI users was significantly higher than in non-PPI users [RR= 2.10, 95% CI (1.17-3.97)]. The risk of gastric cancer was similar between the 2 groups when the duration was ≤1 year [RR= 2.18, 95% CI (0.66-7.11)]. While the risk of gastric cancer for PPI users was higher than in non-PPI users when the duration was between 1-3 years, ≥1 year, ≥3 years and ≥5 years. The risk of non-cardiac gastric cancer for PPI users was higher than for non-PPI users [RR= 2.66, 95% CI (1.66 -4.27)], and the risk of non-cardiac gastric cancer for PPI users was higher than for non-PPI users when the duration ≥1 year [RR= 1.99, 95% CI (1.03-3.83)], but the risk for cardiac gastric cancer was similar between the 2 groups [RR= 1.86, 95% CI (0.71-4.89)]. Conclusions: We found the long-term use of PPI (duration ≥1 year) was significantly associated with a higher risk of non-cardiac gastric cancer.

Download Full-text